Orexin-A manipulation in AD cognition and circadian dysfunction
Orexin-A may be therapeutic only when the intervention restores circadian phase and sleep architecture. Nighttime OX1R/OX2R antagonism could improve glymphatic clearance, whereas daytime orexin tone may support attention and synaptic function.
The same arousal pathway can increase amyloid production by extending wakefulness. A rescue claim must show that benefits are not merely sedation, reduced activity, or nonspecific sleep extension.
The translational path is feasible because orexin receptor antagonists are clinically available. Trials would need actigraphy, polysomnography, plasma/CSF p-tau or Abeta markers, and next-day cognitive safety monitoring.
Ranked synthesis: circadian-timed receptor antagonism is strongest, glymphatic-clearance rescue is the key mechanism to test, and daytime orexin support remains speculative but worth biomarker-led study.